Voyager director granted options on 30K shares

Voyager Therapeutics director Grace Colon received a grant of stock options covering 30,000 shares of common stock.

Rhea-AI Filing Summary

Voyager Therapeutics director Grace Colon received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. They were granted under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.

All 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided Colon continues to serve as a director through that date. This is a routine, compensation-related equity award rather than an open‑market stock purchase or sale.

Insights

Equity compensation analyst

Routine director option grant with time-based vesting, no open-market trading.

Voyager Therapeutics granted director Grace Colon stock options for 30,000 shares at an exercise price of $3.43 per share, expiring on June 9, 2036. The award comes under the 2025 Stock Incentive Plan and aligns with the stated director compensation policy.

The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to continued board service. As a compensation grant (code A) with no same-day sale and no cash changing hands yet, this is generally viewed as routine and carries limited signaling value about the director’s view of the stock.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Colon Grace

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct)

Footnotes (1)

1. F1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Key Figures

Option grant size: 30,000 shares Exercise price: $3.43 per share Option expiration: June 9, 2036 +1 more

4 metrics

Option grant size 30,000 shares Stock Option (Right to Buy) granted to director Grace Colon

Exercise price $3.43 per share Stock option exercise price for 30,000-share grant

Option expiration June 9, 2036 Expiration date of the stock option grant

Underlying common shares 30,000 shares Common stock underlying the stock option grant

Key Terms

Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2025 Stock Incentive Plan financial

"issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."

director compensation policy financial

"in accordance with its director compensation policy"

vesting commencement date financial

"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of stockholders financial

"underlying the option vest upon the earlier of the one-year anniversary ... or the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Voyager Therapeutics (VYGR) disclose in this Form 4 for Grace Colon?

Voyager Therapeutics reported that director Grace Colon received a stock option grant for 30,000 shares of common stock. The award was issued under the 2025 Stock Incentive Plan as part of the company’s director compensation policy and is not an open-market stock purchase or sale.

How many Voyager Therapeutics (VYGR) shares are covered by Grace Colon’s new options?

The Form 4 shows Grace Colon was granted stock options covering 30,000 shares of Voyager Therapeutics common stock. These options give her the right to buy that number of shares in the future at the fixed exercise price, subject to vesting conditions and expiration terms.

What is the exercise price and expiration date of Grace Colon’s Voyager (VYGR) stock options?

Grace Colon’s stock options have an exercise price of $3.43 per share and expire on June 9, 2036. This means she may choose to purchase shares at $3.43 any time after vesting, up until the options expire, subject to the plan’s rules.

How do Grace Colon’s Voyager (VYGR) options vest according to the Form 4?

All 30,000 shares underlying Grace Colon’s options vest in a single tranche. Vesting occurs on the earlier of one year from the grant date or the next annual stockholder meeting, provided she continues to serve as a director through that vesting date, as described in the footnote.

Is Grace Colon’s Voyager (VYGR) option grant an open-market share purchase?

No, the filing describes Grace Colon’s transaction as a grant or award of stock options under Voyager’s 2025 Stock Incentive Plan. This is equity-based compensation, not an open-market purchase or sale of common stock, and involves no immediate cash outlay or trading in the company’s shares.

Was Grace Colon’s Voyager (VYGR) option grant made under a specific compensation plan?

Yes, the footnote explains that the stock option was issued under Voyager Therapeutics’ 2025 Stock Incentive Plan in accordance with its director compensation policy. This indicates the grant is part of the company’s standard approach to compensating board members with equity incentives subject to vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Colon Grace

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.43	06/09/2026		A		30,000		(1)	06/09/2036	Common Stock	30,000	$0	$30,000	D

Explanation of Responses:

1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Grace Colon	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)